The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Molecular Partners AG's 9-Day RSI or its related term are showing as below:
XSWX:MOLN's 9-Day RSI is ranked better than 57.1% of 1422
companies
in the Biotechnology industry
Industry Median: 50.355
vs XSWX:MOLN: 60.27
Molecular Partners AG (XSWX:MOLN) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Molecular Partners AG 9-Day RSI Related Terms
XSWX:MOLN vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Molecular Partners AG's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's 9-Day RSI falls into.
Molecular Partners AG (XSWX:MOLN) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (XSWX:MOLN) has a 9-Day RSI of 60.27 as of Jul. 03, 2026. According to the industry distribution chart, Molecular Partners AG ranks #610 out of 1422 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Molecular Partners AG's 9-Day RSI too high?
Molecular Partners AG's current 9-Day RSI is 60.27. The Biotechnology industry median 9-Day RSI is 50.36. Molecular Partners AG's value of 60.27 is 19.7% above this industry median. Based on the distribution chart, Molecular Partners AG ranks #610 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #610 out of 1422 companies for 9-Day RSI. This puts Molecular Partners AG in the upper half of its industry. The industry median 9-Day RSI is 50.36. Molecular Partners AG's value of 60.27 is 19.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.36, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current 9-Day RSI of 60.27 is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current 9-Day RSI is 60.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (XSWX:MOLN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.37, compared to a current price of CHF3.20 — trading 764.9% above its estimated fair value. The current 9-Day RSI is 60.27 and 19.7% above the Biotechnology industry median of 50.36. Molecular Partners AG's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current 9-Day RSI is 60.27 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of CHF3.20 is trading 764.9% above its estimated GF Value™ of CHF0.37.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for XSWX:MOLN:
9-Day RSI: 60.27
GF Value™: CHF0.37 vs. price of CHF3.20 (764.9% above fair value)
Industry Position: 19.7% above the Biotechnology median (#610 of 1422)
No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score
Get the complete analysis for XSWX:MOLN
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOLN has been successfully added to your 